- Home
- GROW vs AKTX Comparison
GROW vs AKTX Comparison
Compare GROW & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | AKTX |
|---|---|---|
| Founded | 1968 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 14.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GROW | AKTX |
|---|---|---|
| Price | $2.43 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 45.0K | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $8,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $0.26 |
| 52 Week High | $2.78 | $1.73 |
Technical Indicators
Market Signals| Indicator | GROW | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 38.41 |
| Support Level | $2.36 | $0.26 |
| Resistance Level | $2.50 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 54.90 | 37.18 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.